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,81H-globulin is a recently characterized plasma pro-
tein which regulates the biologic activities of the major 
fragment of the third complement component, C3b. The 
lUajor function of this protein is to act as a co-factor for 
C3b Inactivator (C3bINA) in the cleavage of C3b to an 
intermediate molecule, C3b', consisting of an intact {3-
chain covalently bound by disulfide bridges to 2 a-chain 
fragments of 40,000 and 67,000 daltons. Final cleavage of 
C3b'to the C3c and C3d fragments requires an additional 
protease such as plasmin or elastase. Additionally, {31H 
interferes with the activity of the alternative pathway 
convertases, C3bBb and C3bBbP, by displacing or com-
peting with the binding of factor B. 
In this study, perilesional skin biopsies from 10 pa-
tients with active bullous pemphigoid were examined for 
the presence of {31H at the dermal-epidermal junction by 
inununotluorescent methods. The protein was found in 
8 of 9 biopsies in which C3 also was deposited. In a single 
case where C3 was not found, {31H was not seen. These 
findings suggest that {31H plays a role in the in vivo 
control of C3b and provides additional evidence for the 
Participation of the complement system in the pathogen-
esis of bullous pemphigoid. 
Activation of the complement system results in the produc-
tion of substances that play major roles in inflammation [1]. 
One of the products of activation is the major fragment of C3, 
C3b which contributes to the initiation of the terminal lytic seq~ence [2], immune adherence [3] and phagocytosis [4], and 
the release of anaphylatoxic [5] and chemotactic [6] factors. 
C3b may be generated by either the classical pathway of com-
plement activation involving immunoglobulin and factors C1, 
C4, and C2 or by the alternative pathway which requires factors 
B, D, and properdin (P) [1]. The complexes C3bBb and C3bBbP 
function as convertases of the alternative pathway in the pro-
duction of additional C3b from native C3 [7,8]. 
The activity of C3b is regulated by several control proteins: 
C3bINA, {31H-globulin, and proteases such as trypsin, plasmin 
and elastase [9-16]. {31H [10], C3bINA [12,13J and human 
leukocyte elastase [17] have been extensively purified and char-
acterized. {31H acts as a potentiating co-factor of C3bINA in 
transforming C3b to the intermediate C3b' [15]. This interme-
diate molecule consists of an intact {3-chain covalently bound 
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by disulfide bridges to 2 a-chain fragments of 40,000 and 67,000 
daltons [13,15]. In contrast to C3bINA which is a protease, the 
action of {31H is possibly of a nonenzymatic nature. The in vitro 
cleavage ofC3b' to the inactive fragments C3c and C3d requires 
either trypsin, plasmin or elastase [11,13,15]. Also, {31H appears 
to be the primary factor in accelerating the decay of alternative 
pathway convertases C3bBb and C3bBbP by competing with 
the binding of factor B to C3b or by displacing factor B from 
the performed convertases [12,14,16]. 
A role for complement activation in subepidermal blister 
formation has been postulated in bullous pemphigoid [18,19]. 
Patients have circulating anti basement membrane zone anti-
bodies capable of fixing complement [20,21J thus depositing 
immunoglobulin and complement at the basement membrane 
zone in vivo [21,22]. The deposition of complement has been 
shown to involve the classical and alternative pathways of 
complement activation [23,24]. Complement activation may 
lead to blister formation by damaging basal cell membranes, 
attracting inflammatory cells and stimulating the release of 
lysosomal enzymes or activating the release of inflammatory 
mediators from dermal mast cells [26]. Recently, demonstration 
of {31H together with C3 in the skin of patients with SLE [27] 
and in the glomeruli of patients with a variety of immune-type 
renal diseases [28] suggests that {31H might playa role in the in 
vivo control of the biologic activities of complement. 
MATERIALS AND METHODS 
Patients 
Ten patients, 4 males and 6 females, ages 62-84 with active bullous 
pemphigoid were studied. ALI patients were diagnosed by established 
criteria which included an acquired bullous eruption of the skin and a 
subepidermal blister documented by routine light microscopy. By im-
munofluorescence microscopy, the linear deposition of immunoglobulin 
G (IgG) and/ or complement were demonstrated at the dermal epider-
mal junction (DEJ). 
Tissue 
Three-mm punch biopsy specimens of clinically-normal perilesional 
skin were taken under local J % xylocaine anesthesia. Normal human 
skin for use in the indirect complement fIXation assay W/ilS obtained 
from healthy patients undergoing surgery for removal of benign skin 
tumors or inclusion cysts. All specimens were immediately frozen in 
liquid nitrogen and thereafter stored at -70°C. Five Jlm sections were 
cut in a cryostat and airdried on microscope slides just prior to immu-
nofluorescent staining. 
Antisera 
Fluorescein isothiocynate (FITC) conjugated goat anti-human IgG 
and anti-C3 were purchased from Hyland Laboratories (Costa Mesa, 
Ca.). The specificity of these reagents was determined by double 
immunodiffusion and immunoelectrophoresis against purified antigen 
and whole normal human serum. FITC to protein (F:P) ratios for the 
anti·lgG reagent ranged from 2.8-3.0 and from 2.7-3.0 for the anti-C3. 
Anti-human /llH was produced in goats with highly purified ,BIH as 
previously described [10]. The anti-,81H was used in an indirect im-
munofluorescence technique employing FITC-conjugated rabbit anti-
goat IgG (Cappel Labs., Inc., Cochranville, Pa.) as the second antibody. 
The specificity of the anti-,B IH and its lack of cross-reactivity with C3 
and C3bINA was determined using Sepharose beads coated with ,BIH, 
C3~INA and C3 as previously described [27,28]. The staining of,81H at 
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the DEJ of several skin biopsies from patients with bullous pemphigoid 
also was inhibited by reacting the anti-/llH with highly purified ,BIH. 
Additional controls included the staining of all biopsies with FITC-
conjugated ra bbit anti-goat IgG wihout prior treatment with anti-,BIH; 
in no case was positive fluorescence observed. The intensity of staining 
with FITC-conjugated-anti-C3 on biopsy material from patients with 
bullous pemphigoid was not affected by prior absorption of the reagent 
with purified ,B1H. 
Immunofluorescent Technique 
Direct (for C3 and IgG) and indirect (for ,BIH) immunofuorescence 
techniques were used in staining the cryostat sections of skin using the 
methods of Beutner and Nisengard [29]. All antisera were used at the 
highest dilution capable of producing positive fluorescence. The final 
antibody protein concentration of antisera used in staining was I451lg/ 
ml for the FITC-anti-IgG, 170 Ilg/ml for the FITC-anti C3, 150 Ilg/ml 
for the FITC antigoat and 109 Ilg/ ml for the anti-,B1H. 
An arbitrary grading scale of fluorescent intensity was used: 0 = no 
staining, 1 + = minimal staining, 2+ = moderate staining and 3+ = 
heavy staining. 
Indirect Complement and ,BIH Fixation 
A previously described method of complement fixation [20] was used 
to determine if pemphigoid antibody could mediate the in vitro depo-
sition of ,B1H at the DEJ of normal human skin. Sera obtained from 2 
patients with active bullous pemphigoid were used. Antibody titers 
were 1:1280 and 1:640 and both fixed C3 at a diltuion of 1:160. 
Fresh frozen normal human AB serum diluted 1:5 with Ca++ and 
Mg++ enriched PBS was used as the source of complement and ,BIH. 
The antisera, Inactivated by heating to 56°C for 30 min were diluted 1: 
20 with the normal human AB serum and reacted with 5 Il sections of 
normal human skin for 30 min at room temperature. The sections were 
then processed for immunofluorescence by the previously described 
methods. Controls consisted of reacting the tissue section with heat 
inactivated normal human serum and the serum from the patients with 
bullous pemphigoid as well as the other controls described above. 
RESULTS 
The results of staining for IgG, C3 and ,BIH in bullous 
pemphigoid skin are shown in the Table. IgG deposits in a 
linear pattern were demonstrated in all 10 biopsies at the DEJ. 
Nine of the 10 biopsies had C3 depositied in the same pattern. 
Of the 9 biopsies with C3 deposits, 8 also contained deposits of 
,B1H. The staining pattern was also linear. The one biopsy (E 
Du) without C3 staining also failed to demonstrate ,BIH stain-
ing. In all cases, the intensity of the ,B1H staining, was less than 
that of C3. An example of the immunofluorescence for C3 and 
,BIH (patient LI) is demonstrated in Fig 1 and 2 respectively. 
By indirect complement fixation assay, both pemphigoid sera 
tested with C3 as well as ,BIH resulted in a linear fluorescing 
pattern at the DEJ of normal skin. Absorption of anti-,B1H with 
purilled ,BIH completely blocked the reaction. 
DISCUSSION 
The activated third component of complement, C3b, is one 
of the most biologically active fragments of the complement 
system. It mediates immune adherence [3], phagocytosis [4], 
activates the lytic sequence, C5 to C9 [2] and releases anaphy-
/31 H, C3 and IgG immunofluorescence in shin of patients with active 
bullous pemphigoid 
Patient ,81 H C3 IgG 
SN 1+ 3+ 3+ 
LE 0 2+ 2+ 
RC 1+ 2+ 2+ 
EB 2+ 3+ 3+ 
EDu 0 0 3+ 
FFt 1+ 2+ 2+ 
GC 1+ 2+ 2+ 
LFm 1+ 3+ 3+ 
LI 2+ 3+ 2+ 
EM 1+ 3+ 2+ 
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FIG 1. 51l section of skin from patient, LI, stained with goat antihu-
man C3. (X 400). 
FIG 2. Adjacent 5,.,. section from same patient stained for ~IH by 
indirect immunofluorescence at the dermal-epidermal junction identi-
cal to C3 pattern. (x 400) . 
latoxic [5] and chemotactic factors [6]. The production and 
fragmentation of C3b are important events in complement 
mediated inflammation. Conversion of C3 to C3b may be pro-
duced by the classical C3 convertase, C42, or the alternative 
pathway convertases C3bBb and C3bBbP. Fragmentation of 
C3b to the inactive fragments C3c and C3d is mediated by 
C3bINA [9], ,B1H-globulin [10,13,14], trypsin [11,13,15], plasmin 
[11] and elastase [15]. ,BIH-globulin, also known as C3b inacti-
vator accelerator, is one of the most abundant complement 
proteins in plasma (280 Ilg/m1) [10]. It has a molecular weight 
of 150,000 daltons and functions with and without C3b inacti-
vator in regulating C3b activity [10). In vitro studies have 
shown an absolute requirement for ,BIH in the conversion of 
fluid phase C3b to the inactive products C3c and C3d by 
C3bINA [13]. ,B1H also binds to and blocks the activity of 
erythrocyte-bound C3b [11,14,16]. Evidence for this includes 
the demonstration of ,BIH binding to C3b coated cells by both 
irnmunofluorescene and radioactive tracer techniques (16) and 
by studies showing inhibition of complement mediated eryth-
rocyte hemolysis by ,BIH [30]. 
Studies using erythrocytes have shown that ,BIH inhibits the 
formation of the alternative pathway convertases C3bBb and 
C3bBbP [10,16]. It has also been shown that ,BIH accelerates 
the decay-dissociation of preformed alternative pathway con-
vertases in a dose-related, first-order fashion and the loss in 
convertase activity is related to the release of cell-bound 1251_ 
labeled-factor B from the convertase (16). 
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A role for ,BIR in regulating complement activity in vivo is 
supported by studies showing that ,BlR is deposited with com-
plement and immunoglobulin at the DEJ of both lesional and 
nonlesional skin in patients with systemic lupus erythematosus 
[27]. Further evidence comes from similar findings in patients 
with a variety of immune complex mediated renal diseases in 
which ,BIR was found in every instance where C3 was demon-
strated [28]. 
This study provides evidence for the role of ,BIR, a cofactor 
of C3bINA, in regulating complement activity in bullous pem-
phigoid. The protein was found in 8 of 9 skin biopsies from 
patients with active bullous pemphigoid in which C3 was also 
demonstrated. In the single case (E Du) where C3 was absent, 
no ,BIR was found. The immunofluorescent pattern of ,BIR 
staining was identical to that of C3 (linear deposits at the DEJ), 
suggesting an association between the 2 proteins. 
Evidence that ,BIR is involved in complement regulation was 
also suggested by our studies showing that ,BIR is deposited at 
the DEJ by complement fixing pemphigoid antibody. This is 
the first demonstration in man that complement fixation by a 
naturally occurring antibody is associated with simultaneous 
deposition of ,BIR protein. 
A definite role for complement activation in the pathogenesis 
of bullous pemphigoid blisters remains to be established. Evi-
dence favoring a role for complement in bullous pemphigoid 
includes the deposition of both classical and alternative path-
way components at the exact anatomical site of blister forma-
tion [22-24, 31- 33), the ability of many pemphigoid sera to fix 
complement in vitro [34], and the findings of decreased individ-
ual component levels including factor B in blister fluids [33]. 
Additional evidence includes the finding of complement-fixing 
Unmune complexes in serum and blister fluids [35] and comple-
ment dependent chemotactic activity in blister fluids [36]. 
The presence of the regulatory protein, ,BlH, in the skin of 
patients with bullous pemphigoid provides additional evidence 
for the participation of the complement system in the patho-
genesis of the disease. 
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